v3.26.1
Sage Acquisition - Schedule of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
 5 Months Ended
Dec. 31, 2025
Jul. 31, 2025
Dec. 31, 2025
Mar. 31, 2026
Dec. 31, 2024
Business Combination [Line Items]          
Goodwill $ 124,882   $ 124,882 $ 120,668 $ 117,019
Fair value of contingent consideration 31,258   31,258 $ 206  
Sage Therapeutics, Inc.          
Business Combination [Line Items]          
Cash and cash equivalents 243,197 $ 243,197 243,197    
Marketable securities 93,181 93,181 93,181    
Accounts receivable, net 23,291 23,291 23,291    
Inventories, net 52,611 50,714 52,611    
Adjustment, Inventories, net     1,897    
Prepaid expenses and other current assets 16,580 18,674 16,580    
Adjustment, Prepaid expenses and other current assets     (2,094)    
Restricted cash 1,450 1,450 1,450    
Operating lease asset 5,110 5,630 5,110    
Adjustment, operating lease asset     (520)    
Intangible assets 142,900 166,500 142,900    
Adjustment, Intangible assets     (23,600)    
Deferred income tax assets, net 46,698   46,698    
Adjustment, deferred income tax assets, net     46,698    
Other assets 1,102 1,102 1,102    
Total fair value of assets acquired 626,120 603,739 626,120    
Adjustment, Total fair value of assets acquired     22,381    
Accounts payable and accrued liabilities 44,232 44,232 44,232    
Other liabilities 23,969   23,969    
Adjustment, other liabilities     23,969    
Operating lease liability 12,380 12,380 12,380    
Total fair value of liabilities assumed 80,581 56,612 80,581    
Adjustment, Total fair value of liabilities assumed     23,969    
Total identifiable net assets 545,539 547,127 545,539    
Adjustment, Total identifiable net assets     (1,588)    
Goodwill 3,649 2,061 3,649    
Adjustment, Goodwill     1,588    
Total purchase price 549,188 549,188 549,188    
Cash consideration paid for Sage's common stock   561,000      
Cash consideration paid for cash settlement of Sage's equity awards 4,073 4,073      
Fair value of contingent consideration 11,448 11,448 $ 11,448    
Sage Therapeutics, Inc. | Common Stock          
Business Combination [Line Items]          
Cash consideration paid for Sage's common stock $ 533,667 $ 533,667